TP53 and cancer: It should be noted that TP53 is frequently mutated in AML with complex karyotype83,84, which may account for relatively higher HSF1 mRNA expression in AML with complex karyotype (Supplementary Fig. 4b, c) given that wild type TP53 suppresses HSF1 expression and the mutant cancer genome85.